|Videos|November 20, 2017

Vaccination Plays a Crucial Role in Reducing Inappropriate Antibiotic Use

James S. Lewis, PharmD, FIDSA, discusses the role vaccination plays in reducing unnecessary antibiotic use.

James S. Lewis, PharmD, FIDSA, Co-Director of Antibiotic Stewardship, Oregon Health and Science University, discusses the role vaccination plays in reducing unnecessary antibiotic use.

Interview Transcript (modified slightly for readability):

"Vaccination is massive in preventing inappropriate antibiotic use because if you don’t get sick, you don’t think you need an antibiotic. The flu vaccine—rightly or wrongly—has a very bad rap for how ineffective it is; oh, it’s only 60% effective. Sixty percent effective is still a whole heck of a lot better than zero percent effective. And when folks end up with the flu, far too often, incorrectly, they end up with an antibiotic prescription. Pneumococcal vaccines are another great example of an area where vaccines have the potential to prevent diseases that lead then to subsequent antibiotic use, which then leads to the development of resistance. So, I think vaccination has got to be a core piece of any sort of strategy to try to minimize antibiotic use in the long run because you don’t need antibiotics if you don’t get sick, and that’s what vaccines are really here to do."


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.